The past, present, and future of nicotine addiction therapy

Annual Review of Medicine

Volumn 67, Issue , 2016, Pages 467-486

  Prochaska, Judith J ^a   Benowitz, Neal L ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cessation; Cigarette; Quitline; Smoking; Tobacco; Vape

Indexed keywords

AMFEBUTAMONE; CYTISINE; NICOTINE; NICOTINE GUM; NICOTINE LOZENGE; NICOTINE PATCH; VARENICLINE; ALKALOID; AZOCINE DERIVATIVE; DOPAMINE UPTAKE INHIBITOR; NICOTINIC AGENT; QUINOLIZINE DERIVATIVE;

ARTICLE; BEHAVIOR THERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); GROUP THERAPY; HEALTH CARE POLICY; HUMAN; META ANALYSIS (TOPIC); NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING CESSATION; SOCIAL MEDIA; TOBACCO DEPENDENCE; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; DIRECTIVE COUNSELING; METABOLISM; PROCEDURES; TEXT MESSAGING; TOBACCO USE DISORDER;

ALKALOIDS; AZOCINES; BUPROPION; DIRECTIVE COUNSELING; DOPAMINE UPTAKE INHIBITORS; DRUG THERAPY, COMBINATION; HEALTH POLICY; HUMANS; NICOTINE; NICOTINIC AGONISTS; QUINOLIZINES; SMOKING CESSATION; SOCIAL MEDIA; TEXT MESSAGING; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER; VARENICLINE;

EID: 84954565646     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-111314-033712     Document Type: Article

References (95)

1. US Department of Health and Human Services. (2014). The health consequences of smoking-50 years of progress. Rep. Surgeon General, US Dep. Health Hum. Serv., Cent. Disease Control Prev., Natl. Cent. Chronic Disease Prev. Health Promot., Off. Smoking Health, Atlanta, GA
2. World Lung Foundation. (2015). The Tobacco Atlas. Atlanta, GA: Am. Cancer Soc. 5th e.d
3. Jamal A, Agaku IT, O'Connor E, et al. (2014). Current cigarette smoking among adults-United States, 2005-2013. Morb. Mortal. Wkly. Rep. 63: 1108-12
4. US Department of Health and Human Services. (2012). Preventing tobacco use among youth and young adults. Rep. Surgeon General, US Dep. Health Hum. Serv., Cent. Disease Control Prev., Natl. Cent. Chronic Disease Prev. Health Promot., Off. Smoking Health, Atlanta, GA
5. Benowitz NL. (2010). Nicotine addiction. N. Engl. J. Med. 362: 2295-303
6. Benowitz NL. (2009). Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu. Rev. Pharmacol. Toxicol. 49: 57-71
7. Hall SM, Prochaska JJ. (2009). Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings. Annu. Rev. Clin. Psychol. 5: 409-31
8. Fiore MC, Jaén CR, Baker TB, et al. (2008). Treating tobacco use and dependence: 2008 update. Rep. US Dep. Health Hum. Serv., Public Health Serv., Rockville, MD
9. Cahill K, Stevens S, Perera R, Lancaster T. (2013). Pharmacological interventions for smoking cessation: an overview and network meta-Analysis. Cochrane Database Syst. Rev. 5: CD009329
10. Fiore MC, Jaen CR. (2008). A clinical blueprint to accelerate the elimination of tobacco use. JAMA 299: 2083-85
11. Fucito LM, Bars MP, Forray A, et al. (2014). Addressing the evidence forFDAnicotine replacement therapy label changes: a policy statement of the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco. Nicotine Tobacco Res. 16: 909-14
12. Hajek P, West R, Foulds J, et al. (1999). Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch. Intern. Med. 159: 2033-38
13. Stead LF, Perera R, Bullen C, et al. (2012). Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 11: CD000146
14. Slemmer JE, Martin BR, Damaj MI. (2000). Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Ther. 295: 321-27
15. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. (2003). Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology 168: 347-58
16. Hurt RD, Sachs DP, Glover ED, et al. (1997). A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. 337: 1195-202
17. Hays JT, Hurt RD, Rigotti NA, et al. (2001). Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann. Intern. Med. 135: 423-33
18. Gonzales D, Rennard SI, Nides M, et al. (2006). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist versus sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296: 47-55
19. Evins AE, Cather C, Pratt SA, et al. (2014). Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA 311: 145-54
20. Tonstad S, Tonnesen P, Hajek P, et al. (2006). Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296: 64-71
21. Cinciripini PM, Robinson JD, Karam-Hage M, et al. (2013). Effects of varenicline and bupropion sustainedrelease use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry 70: 522-33
22. Williams JM, Anthenelli RM, Morris CD, et al. (2012). A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J. Clin. Psychiatry 73: 654-60
23. Anthenelli RM, Morris C, Ramey TS, et al. (2013). Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann. Intern. Med. 159: 390-400
24. Pasternak B, Svanstrom H, Hviid A. (2013). Use of varenicline versus bupropion and risk of psychiatric adverse events. Addiction 108: 1336-43
25. Thomas KH, Martin RM, Davies NM, 2013. Smoking cessation treatment and risk of depression, suicide, and self harm in the Clinical Practice Research Datalink: prospective cohort study. BMJ 347: f5704
26. Oquendo MA, Galfalvy H, Russo S, et al. (2004). Prospective study of clinical predictors of suicidal acts after a major depressive episode in patients with major depressive disorder or bipolar disorder. Am. J. Psychiatry 161: 1433-41
27. Singh S, Loke YK, Spangler JG, Furberg CD. (2011). Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-Analysis. Can. Med. Assoc. J. 183: 1359-66
28. Prochaska JJ, Hilton JF. (2012). Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-Analysis. BMJ 344: e2856
29. National Comprehensive Cancer Network. (2015). Clinical practice guidelines in oncology: smoking cessation. Natl. Compr. Cancer Netw., FortWashington, PA
30. Koegelenberg CF, Noor F, Bateman ED, et al. (2014). Efficacy of varenicline combined with nicotine replacement therapy versus varenicline alone for smoking cessation: a randomized clinical trial. JAMA 312: 155-61
31. Hajek P, Smith KM, Dhanji AR, McRobbie H. (2013). Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial. BMC Med. 11: 140
32. Ebbert JO, Hays JT, Hurt RD. (2010). Combination pharmacotherapy for stopping smoking: What advantages does it offer? Drugs 70: 643-50
33. Ebbert JO, Hatsukami DK, Croghan IT, et al. (2014). Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA 311: 155-63
34. Hong AS, Elrashidi MY, Schroeder DR, Ebbert JO. (2015). Depressive symptoms among patients receiving varenicline and bupropion for smoking cessation. J. Subst. Abuse Treat. 52: 78-81
35. Shiffman S, Ferguson SG. (2008). Nicotine patch therapy prior to quitting smoking: a meta-Analysis. Addiction 103: 557-63
36. Bullen C, Howe C, Lin RB, et al. (2010). Pre-cessation nicotine replacement therapy: pragmatic randomized trial. Addiction 105: 1474-83
37. Carpenter MJ, Jardin BF, Burris JL, et al. (2013). Clinical strategies to enhance the efficacy of nicotine replacement therapy for smoking cessation: a review of the literature. Drugs 73: 407-26
38. Lindson N, Aveyard P, Hughes JR. (2010). Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst. Rev. 11: CD008033
39. Ebbert JO, Hughes JR, West RJ, et al. (2015). Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA 313: 687-94
40. Lerman C, Schnoll RA, Hawk LW Jr, et al. (2015). Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir. Med. 3: 131-38
41. Gourlay SG, Benowitz NL. (1995). Is clonidine an effective smoking cessation therapy? Drugs 50: 197-207
42. Hajek P, McRobbie H, Myers K. (2013). Efficacy of cytisine in helping smokers quit: systematic review and meta-Analysis. Thorax 68: 1037-42
43. Cahill K, Stead LF, Lancaster T. (2012). Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev. 4: CD006103
44. World Health Organization (2013). WHO report on the global tobacco epidemic, 2013: enforcing bans on tobacco advertising, promotion and sponsorship, World Health Org., Geneva
45. Walker N, Howe C, Glover M, et al. (2014). Cytisine versus nicotine for smoking cessation. N. Engl. J. Med. 371: 2353-62
46. Stead LF, Buitrago D, Preciado N, et al. (2013). Physician advice for smoking cessation. Cochrane Database Syst. Rev. 5: CD000165
47. Prochaska JJ, Benowitz NL, Glantz SA, et al. (2011). Cardiology Rx for change: improving clinical attention to tobacco use and secondhand smoke exposure in cardiology. Clin. Cardiol. 34: 738-43
48. Prochaska JJ, Fromont SC, Leek D, et al. (2008). Evaluation of an evidence-based tobacco treatment curriculum for psychiatry residency training programs. Acad. Psychiatry 32: 484-92
49. Carson KV, Verbiest ME, Crone MR, et al. (2012). Training health professionals in smoking cessation. Cochrane Database Syst. Rev. 5: CD000214
50. Lancaster T, Stead LF. (2005). Individual behavioural counselling for smoking cessation. Cochrane Database Syst. Rev. 2: CD001292
51. Stead LF, Lancaster T. (2005). Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst. Rev. 2: CD001007
52. Stead LF, Lancaster T. (2012). Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst. Rev. 10: CD008286
53. Hall SM, Humfleet GL, Munoz RF, et al. (2009). Extended treatment of older cigarette smokers. Addiction 104: 1043-52
54. Schnoll RA, Goelz PM, Veluz-Wilkins A, et al. (2015). Long-Term nicotine replacement therapy: a randomized clinical trial. JAMA Intern. Med. 175: 504-11
55. Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. (2013). Telephone counselling for smoking cessation. Cochrane Database Syst. Rev. 8: CD002850
56. Severson HH, Akers L, Andrews JA, et al. (2000). Evaluating two self-help interventions for smokeless tobacco cessation. Addict. Behav. 25: 465-70
57. Schauer GL, Malarcher AM, Zhang L, et al. (2013). Prevalence and correlates of quitline awareness and utilization in the United States: an update from the 2009-2010 National Adult Tobacco Survey. Nicotine Tob. Res. 2013: 1-10
58. Civljak M, Stead LF, Hartmann-Boyce J, et al. (2013). Internet-based interventions for smoking cessation. Cochrane Database Syst. Rev. 7: CD007078
59. Fraser D, Kobinsky K, Smith SS, et al. (2014). Five population-based interventions for smoking cessation: a MOST trial. Transl. Behav. Med. 4: 382-90
60. Free C, Knight R, Robertson S, et al. (2011). Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial. Lancet 378: 49-55
61. Kong G, Ells DM, Camenga DR, Krishnan-Sarin S. (2014). Text messaging-based smoking cessation intervention: a narrative review. Addict. Behav. 39: 907-17
62. Duggan M, Smith A. (2013). Social media update 2013. Pew Res. Cent., Washington, DC. http://www. pewinternet.org/2013/12/30/social-media-update-2013/
63. Prochaska JJ, Pechmann C, Kim R, Leonhardt JM. (2012). Twitter = quitter? An analysis of Twitter quit smoking social networks. Tob. Control 21: 447-49
64. Stoddard JL, Augustson EM, Moser RP. (2008). Effect of adding a virtual community (bulletin board) to smokefree.gov: randomized controlled trial. J. Med. Internet Res. 10: e53
65. Danaher BG, Boles SM, Akers L, et al. (2006). Defining participant exposuremeasures inWeb-based health behavior change programs. J. Med. Internet Res. 8(3): e15
66. An LC, Schillo BA, Saul JE, et al. (2008). Utilization of smoking cessation informational, interactive, and online community resources as predictors of abstinence: cohort study. J. Med. Internet Res. 10: e55
67. May S, West R. (2000). Do social support interventions (buddy systems) aid smoking cessation? A review. Tob. Control 9: 415-22
68. May S, West R, Hajek P, et al. (2006). Randomized controlled trial of a social support ('buddy') intervention for smoking cessation. Patient Educ. Couns. 64: 235-41
69. West R, Edwards M, Hajek P. (1998). A randomized controlled trial of a buddy system to improve success at giving up smoking in general practice. Addiction 93: 1007-11
70. Pechmann C, Pan L, Delucchi K, et al. (2015). Development of a Twitter-based intervention for smoking cessation that encourages high quality social media interactions through automessages. J. Med. Internet Res. 17: e50
71. Haines-Saah RJ, Kelly MT, Oliffe JL, Bottorff JL. (2015). Picture me smokefree: a qualitative study using social media and digital photography to engage young adults in tobacco reduction and cessation. J. Med. Internet. Res. 17: e27
72. Ramo DE, Liu H, Prochaska JJ. (2015). A mixed-methods study of young adults' receptivity to using Facebook for smoking cessation: If you build it, will they come? Am. J. Health Promot. 29: e126-35
73. Cobb NK, Jacobs MA, Saul J, et al. (2014). Diffusion of an evidence-based smoking cessation intervention through Facebook: a randomised controlled trial study protocol. BMJ Open 4: e004089
74. Chapman S. (2013). Should electronic cigarettes be as freely available as tobacco cigarettes? No. BMJ 346
75. Etter J-F. (2013). Should electronic cigarettes be as freely available as tobacco? Yes. BMJ 346
76. Adkison SE, O'Connor RJ, Bansal-Travers M, et al. (2013). Electronic nicotine delivery systems: international tobacco control four-country survey. Am. J. Prev. Med. 44: 207-15
77. Dockrell M, Morrison R, Bauld L, McNeill A. (2013). E-cigarettes: prevalence and attitudes in Great Britain. Nicotine Tob. Res. 15: 1737-44
78. Goniewicz ML, Lingas EO, Hajek P. (2013). Patterns of electronic cigarette use and user beliefs about their safety and benefits: an internet survey. Drug Alcohol Rev. 32: 133-40
79. King BA, Alam S, Promoff G, et al. (2013). Awareness and ever-use of electronic cigarettes among US. adults, 2010-2011. Nicotine Tob. Res. 15: 1623-27
80. Arrazola RA, Singh T, Corey CG, et al. (2015). Tobacco use among middle and high school students-United States, 2011-2014. Morb. Mortal. Wkly. Rep. 64: 381-85
81. Wills TA, Knight R, Williams RJ, et al. (2015). Risk factors for exclusive e-cigarette use and dual e-cigarette use and tobacco use in adolescents. Pediatrics 135: e43-51
82. Goniewicz ML, Knysak J, Gawron M, et al. (2014). Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob. Control 23: 133-39
83. Caponnetto P, Campagna D, Cibella F, et al. (2013). EffiCiency and safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS ONE 8: e66317
84. Bullen C, Howe C, Laugesen M, et al. (2013). Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 382: 1629-37
85. Brose LS, Hitchman SC, Brown J, et al. (2015). Is the use of electronic cigarettes while smoking associated with smoking cessation attempts, cessation and reduced cigarette consumption? A survey with a 1-year follow-up. Addiction 110: 1160-68
86. Hitchman SC, Brose LS, Brown J, et al. (2015). Associations between e-cigarette type, frequency of use, and quitting smoking: findings from a longitudinal online panel survey in Great Britain. Nicotine Tob. Res. 17: 1187-94
87. Cahill K, Perera R. (2011). Competitions and incentives for smoking cessation. Cochrane Database Syst. Rev. 4: CD004307
88. Volpp KG, Troxel AB, Pauly MV, et al. (2009). A randomized, controlled trial of financial incentives for smoking cessation. N. Engl. J. Med. 360: 699-709
89. Volpp KG, Asch DA, Galvin R, Loewenstein G. (2011). Redesigning employee health incentives-lessons from behavioral economics. N. Engl. J. Med. 365: 388-90
90. Hilzenrath DS. (2010). Misleading claims about Safeway wellness incentives shape health-care bill. Washington Post Jan. 17, Sec. G01. http://www.washingtonpost.com/wp-dyn/content/article/2010/01/15/AR2010011503319-pf.html
91. US Department of Health and Human Services. (2000). Reducing tobacco use. Rep. Surgeon General, US Dep. HealthHum. Serv., Cent. DiseaseControl Prev., Natl. Cent.Chronic Disease Prev. Health Promot., Off. Smoking Health, Atlanta, GA
92. Mills AL, Messer K, Gilpin EA, Pierce JP. (2009). The effect of smoke-free homes on adult smoking behavior: a review. Nicotine Tob. Res. 11: 1131-41
93. Kofman M, Dunton K, Senkewicz MB. (2012). Implementation of tobacco cessation coverage under the Affordable Care Act: understanding how private health insurance policies cover tobacco cessation treatments. Health Policy Inst., Georgetown Univ., Washington, DC. http://www.tobaccofreekids.org/pressoffice/2012/georgetown/coveragereport.pdf
94. Richard P, West K, Ku L. (2012). The return on investment of a Medicaid tobacco cessation program in Massachusetts. PLoS ONE 7: e29665
95. Healthy People. (2020). Leading health indicators. US Dep. Health Hum. Serv. Off. Dis. Prevention and Health Promotion, Washington, DC. http://www.healthypeople.gov/2020/Leading-Health-Indicators